Respira Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
Respira Therapeutics to Present Phase 2b Results of RT234 Inhalation Therapy for PAH at ATS 2025
• Respira Therapeutics will present late-breaking results from its Phase 2b trial of RT234, an inhaled vardenafil powder for pulmonary arterial hypertension, at the ATS 2025 International Conference on May 20.
• RT234 is being developed as the first as-needed (PRN) therapy for PAH patients to acutely improve exercise tolerance and reduce exertional symptoms, potentially enhancing daily activities and quality of life.
• The innovative treatment utilizes Respira's proprietary Axial Oscillating Sphere Dry Powder Inhaler technology to maximize drug delivery to the distal lung for optimal therapeutic effect.
© Copyright 2025. All Rights Reserved by MedPath